首页 | 本学科首页   官方微博 | 高级检索  
检索        

首批HPLC-SEC系统适用性免疫球蛋白国家对照品研制
引用本文:王敏力,曹大伟,李庆英,马力,陈家啡,梁蔚阳,何淑琴,余进,李炎,徐苗,侯继锋.首批HPLC-SEC系统适用性免疫球蛋白国家对照品研制[J].中国药学杂志,2022,57(6):491-495.
作者姓名:王敏力  曹大伟  李庆英  马力  陈家啡  梁蔚阳  何淑琴  余进  李炎  徐苗  侯继锋
作者单位:1.中国食品药品检定研究院, WHO生物制品标准化和评价合作中心, 卫生部生物技术产品检定方法及标准化重点实验室, 国家药品监督管理局生物制品质量研究与评价重点实验室, 北京 100050;
2.山东泰邦生物制品有限公司, 山东 泰安 271000;
3.华兰生物工程股份有限公司, 河南 新乡 453003;
4.博雅生物集团股份有限公司, 江西 抚州 344000;
5.广东省药品检验所, 广州 510180;
6.四川远大蜀阳药业有限责任公司, 成都 610214;
7.上海莱士血液制品股份有限公司, 上海 200245;
8.四川省药品检验研究院, 成都 611731
基金项目:国家重大新药创制专项课题资助(2018ZX09101001,2018ZX09301004)
摘    要:目的 研制一种高效液相分子排阻色谱(HPLC-SEC)系统适用性免疫球蛋白国家对照品,用于免疫球蛋白类产品等分子大小分布系统适用性确认。方法 制备符合技术指标要求的静注人免疫球蛋白产品作为对照品原料,合并后进行除菌过滤,最后分装。按照《中国药典》2020年版三部附录中“人免疫球蛋白类制品IgG单体加二聚体测定方法”,在8家实验室进行协作标定,同时进行稳定性监测。结果 8家实验室测定本批对照品单体与裂解物分离度(R)均>1.5(均值为2.3),实验条件均符合《中国药典》2020年版三部中相关要求;8家实验室对照品裂解物峰面积百分比均值为3.83%,95%置信区间(3.48,4.19)%,均>2.0%,满足预期技术要求。在2~8 ℃下持续对该对照品进行14个月稳定性监测,分离度(R)符合《中国药典》要求,裂解物峰面积百分比未发生趋势性变化,建议对照品按2~8 ℃保存和运输。结论 HPLC-SEC系统适用性免疫球蛋白国家对照品可以用于《中国药典》2020年版要求的系统适用性测试,有助于提升免疫球蛋白等产品分子大小分布检测结果可靠性。

关 键 词:血液制品  人免疫球蛋白  系统适用性  分子大小分布  国家对照品  高效液相色谱法  
收稿时间:2021-05-30

Development of the First Batch of National Reference Substance of Immunoglobulin for HPLC-SEC System Suitability Test
WANG Min-li,CAO Da-Wei,LI Qing-ying,MA Li,CHEN Jia-fei,LIANG Wei-yang,HE Shu-qin,YU Jin,LI Yan,XU Miao,HOU Ji-feng.Development of the First Batch of National Reference Substance of Immunoglobulin for HPLC-SEC System Suitability Test[J].Chinese Pharmaceutical Journal,2022,57(6):491-495.
Authors:WANG Min-li  CAO Da-Wei  LI Qing-ying  MA Li  CHEN Jia-fei  LIANG Wei-yang  HE Shu-qin  YU Jin  LI Yan  XU Miao  HOU Ji-feng
Abstract:OBJECTIVE To establish a national reference substance of immunoglobulin for HPLC-SEC system suitability test to confirm the system suitability of HPLC molecular size distribution analytical assay of immunoglobulin products. METHODS Intravenous human immunoglobulin products meeting the technical requirements were prepared as the raw materials of the reference substance, which were treated, combined, sterilized and filtered, and then sub packaged. According to the 2020 edition of Chinese Pharmacopoeia part III human immunoglobulin IgG monomer and dimer determination method, eight laboratories were involved for collaborative calibration. Stability monitoring was also carried out meanwhile. RESULTS The mean value of resolution of monomer vs fragments from the eight laboratories was 2.3, all of which were greater than 1.5, which verified that the experimental conditions met the requirements of Chinese Pharmacopoeia 2020 edition. The inter-lab mean value of peak area% of the national reference substance for immunoglobulin HPLC-SEC system suitability test was 3.83% (95% CI:3.48%-4.19%), all of which were greater than 2.0%, meeting the expected technical requirements. The stability of national reference substance for immunoglobulin HPLC-SEC system suitability test was continuously monitored at 2-8 ℃ for 14 m. The resolution data complied with the requirements of Chinese Pharmacopoeia (R>1.5) and the peak area% of fragments data showed no abnormal trends. It was suggested that the reference substance be stored and transported at 2-8 ℃. CONCLUSIONT The national reference substance of immunoglobulin for HPLC-SEC system suitability test can achieve the system applicability test required by the Chinese Pharmacopoeia 2020 edition, which is helpful to improve the reliability of the molecular size distribution test results of immunoglobulin and other products.
Keywords:blood products                                                      immunoglobulin                                                      system suitability test                                                      molecular-size distribution                                                      national reference substance                                                      high performance liquid chromatography                                      
点击此处可从《中国药学杂志》浏览原始摘要信息
点击此处可从《中国药学杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号